GlassScriptPhysician profile
Gopal N Bhalala
NPI 1669473963
$36,126.99
in general payments reported to CMS, 2019-2025
64 companies · $3,407 in 2025
The $3,407 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,508 · 2020: $3,908 · 2021: $6,146 · 2022: $5,279 · 2023: $4,696 · 2024: $5,182 · 2025: $3,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $36.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,248.48 |
| Education | $36.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,356.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,453.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,797.20 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $2,787.30 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,768.10 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Lilly USA, LLC | $2,269.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $1,641.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $1,247.72 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,120.28 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $1,007.83 | 2023-2025 | Auvelity |
| Pfizer INC. | $1,005.82 | 2019-2025 | |
| Esperion Therapeutics, INC. | $909.84 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $806.49 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $757.25 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Hikma Pharmaceuticals USA | $611.63 | 2019-2025 | Ryaltris, Kloxxado, Mitigare |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Bhalala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.